SCPH
Price
$3.98
Change
+$0.01 (+0.25%)
Updated
Jun 26 closing price
Capitalization
210.11M
40 days until earnings call
YMAB
Price
$4.80
Change
-$0.11 (-2.24%)
Updated
Jun 26 closing price
Capitalization
217.42M
41 days until earnings call
Interact to see
Advertisement

SCPH vs YMAB

Header iconSCPH vs YMAB Comparison
Open Charts SCPH vs YMABBanner chart's image
scPharmaceuticals
Price$3.98
Change+$0.01 (+0.25%)
Volume$162.29K
Capitalization210.11M
Y-mAbs Therapeutics
Price$4.80
Change-$0.11 (-2.24%)
Volume$126.16K
Capitalization217.42M
SCPH vs YMAB Comparison Chart in %
Loading...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SCPH vs. YMAB commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCPH is a StrongBuy and YMAB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (SCPH: $3.98 vs. YMAB: $4.80)
Brand notoriety: SCPH and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SCPH: 50% vs. YMAB: 58%
Market capitalization -- SCPH: $210.11M vs. YMAB: $217.42M
SCPH [@Biotechnology] is valued at $210.11M. YMAB’s [@Biotechnology] market capitalization is $217.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCPH’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 1 green FA rating(s).

  • SCPH’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 1 green, 4 red.
According to our system of comparison, both SCPH and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCPH’s TA Score shows that 4 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • SCPH’s TA Score: 4 bullish, 5 bearish.
  • YMAB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than SCPH.

Price Growth

SCPH (@Biotechnology) experienced а +1.53% price change this week, while YMAB (@Biotechnology) price change was +3.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

SCPH is expected to report earnings on Aug 06, 2025.

YMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($217M) and SCPH($210M) have the same market capitalization . SCPH YTD gains are higher at: 12.429 vs. YMAB (-38.697). YMAB has higher annual earnings (EBITDA): -30.39M vs. SCPH (-83.9M). YMAB (60.3M) and SCPH (57.5M) have equal amount of cash in the bank . YMAB has less debt than SCPH: YMAB (603K) vs SCPH (52.4M). YMAB has higher revenues than SCPH: YMAB (88.7M) vs SCPH (42M).
SCPHYMABSCPH / YMAB
Capitalization210M217M97%
EBITDA-83.9M-30.39M276%
Gain YTD12.429-38.697-32%
P/E RatioN/AN/A-
Revenue42M88.7M47%
Total Cash57.5M60.3M95%
Total Debt52.4M603K8,690%
FUNDAMENTALS RATINGS
SCPH vs YMAB: Fundamental Ratings
SCPH
YMAB
OUTLOOK RATING
1..100
7272
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
4163
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (33) in the Pharmaceuticals Major industry is in the same range as SCPH (61). This means that YMAB’s stock grew similarly to SCPH’s over the last 12 months.

YMAB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SCPH (100). This means that YMAB’s stock grew similarly to SCPH’s over the last 12 months.

YMAB's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as SCPH (100). This means that YMAB’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as YMAB (63). This means that SCPH’s stock grew similarly to YMAB’s over the last 12 months.

SCPH's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as YMAB (100). This means that SCPH’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCPHYMAB
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIUSX32.920.36
+1.11%
Macquarie Opportunity A
GLCRX28.72N/A
N/A
Goldman Sachs Large Cap Gr Insghts R
HGORX59.20N/A
N/A
Hartford Growth Opportunities R3
MAIJX18.92N/A
N/A
Morgan Stanley Inst Passport ovrs eq R6
OWLLX10.39N/A
N/A
Channing Intrinsic Value Sm-Cp Instl

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with CRSP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
+0.25%
CRSP - SCPH
45%
Loosely correlated
-0.17%
BEAM - SCPH
45%
Loosely correlated
+2.27%
AURA - SCPH
44%
Loosely correlated
-4.26%
YMAB - SCPH
43%
Loosely correlated
-2.24%
AVIR - SCPH
43%
Loosely correlated
+1.73%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-2.24%
ARWR - YMAB
53%
Loosely correlated
+2.62%
OCUL - YMAB
51%
Loosely correlated
+2.94%
CRSP - YMAB
50%
Loosely correlated
-0.17%
FATE - YMAB
48%
Loosely correlated
-5.17%
IPSC - YMAB
47%
Loosely correlated
+0.23%
More